Cargando…

Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells

While inhibition of T cell co-inhibitory receptors has revolutionized cancer therapy, the mechanisms governing their expression on human T cells have not been elucidated. Here we show that type 1 interferon (IFN-I) regulates co-inhibitory receptor expression on human T cells, inducing PD-1/TIM-3/LAG...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumida, Tomokazu S., Dulberg, Shai, Schupp, Jonas C., Lincoln, Matthew R., Stillwell, Helen A., Axisa, Pierre-Paul, Comi, Michela, Unterman, Avraham, Kaminski, Naftali, Madi, Asaf, Kuchroo, Vijay K., Hafler, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989655/
https://www.ncbi.nlm.nih.gov/pubmed/35301508
http://dx.doi.org/10.1038/s41590-022-01152-y
Descripción
Sumario:While inhibition of T cell co-inhibitory receptors has revolutionized cancer therapy, the mechanisms governing their expression on human T cells have not been elucidated. Here we show that type 1 interferon (IFN-I) regulates co-inhibitory receptor expression on human T cells, inducing PD-1/TIM-3/LAG-3 while inhibiting TIGIT expression. High-temporal-resolution mRNA profiling of IFN-I responses established the dynamic regulatory networks uncovering three temporal transcriptional waves. Perturbation of key transcription factors (TFs) and TF footprint analysis revealed two regulator modules with different temporal kinetics that control expression of co-inhibitory receptors and IFN-I response genes with SP140 highlighted as one of the key regulators that differentiates LAG-3 and TIGIT expression. Finally, we found that the dynamic IFN-I response in vitro closely mirrored T cell features in acute SARS-CoV-2 infection. The identification of unique TFs controlling co-inhibitory receptor expression under IFN-I response may provide targets for enhancement of immunotherapy in cancer, infectious diseases, and autoimmunity.